Beam Therapeutics is a healthcare company focusing on biotechnology, genetic medicines, and base editing technology. Established in Cambridge, MA, the organization pioneers the use of base editing, aiming to provide lifelong cures for patients suffering from serious diseases. This innovative approach allows for precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA.
Led by CEO John Evans, Beam Therapeutics employs 253 professionals and generates an annual revenue of $60,920,000. The company's portfolio consists of gene correction, gene modification, gene activation, gene silencing, and multiplex editing. With a mission to create a new class of precision genetic medicines, Beam Therapeutics is committed to transforming the lives of patients through its proprietary base editing technology and innovative research.
